- Home
- EU vs PCRX Comparison
EU vs PCRX Comparison
Compare EU & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- PCRX
- Stock Information
- Founded
- EU 2009
- PCRX 2006
- Country
- EU United States
- PCRX United States
- Employees
- EU N/A
- PCRX N/A
- Industry
- EU Other Metals and Minerals
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- EU Basic Materials
- PCRX Health Care
- Exchange
- EU Nasdaq
- PCRX Nasdaq
- Market Cap
- EU 538.3M
- PCRX 1.2B
- IPO Year
- EU N/A
- PCRX 2011
- Fundamental
- Price
- EU $2.98
- PCRX $21.85
- Analyst Decision
- EU Strong Buy
- PCRX Buy
- Analyst Count
- EU 1
- PCRX 8
- Target Price
- EU $2.75
- PCRX $28.38
- AVG Volume (30 Days)
- EU 3.3M
- PCRX 506.9K
- Earning Date
- EU 08-13-2025
- PCRX 07-29-2025
- Dividend Yield
- EU N/A
- PCRX N/A
- EPS Growth
- EU N/A
- PCRX N/A
- EPS
- EU N/A
- PCRX N/A
- Revenue
- EU $46,179,000.00
- PCRX $702,772,000.00
- Revenue This Year
- EU $27.46
- PCRX $7.92
- Revenue Next Year
- EU $140.12
- PCRX $11.02
- P/E Ratio
- EU N/A
- PCRX N/A
- Revenue Growth
- EU N/A
- PCRX 3.08
- 52 Week Low
- EU $1.01
- PCRX $11.16
- 52 Week High
- EU $4.44
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- EU 65.93
- PCRX 33.91
- Support Level
- EU $2.52
- PCRX $22.24
- Resistance Level
- EU $2.93
- PCRX $23.58
- Average True Range (ATR)
- EU 0.18
- PCRX 0.77
- MACD
- EU -0.00
- PCRX -0.05
- Stochastic Oscillator
- EU 91.49
- PCRX 5.16
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.